West German Study Group

This study tests whether a newer drug combination (trastuzumab-deruxtecan, or T-DXd) works better than standard chemotherapy before surgery in people with HER2-positive early breast cancer. About 402 participants will receive either T-DXd or standard chemo, and researchers will c…

This study looks at women with a high-risk type of breast cancer (HR+/HER2-) who have already completed initial treatments like surgery or chemo. The goal is to see if adding the drug abemaciclib to standard hormone therapy helps keep the cancer from returning better than hormone…

This study tests whether a combination of ribociclib (a targeted pill) and hormone therapy works better than standard chemotherapy for women with intermediate-risk, hormone-receptor-positive, HER2-negative early breast cancer. About 1,684 women took part. The goal is to see if th…